BLISS GVS PHARMA LTD (BLISSGVS) financials

BLISS GVS PHARMA LTD (BLISSGVS) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

Market Cap: ₹7,124Cr.
Current Price: ₹673
Stock P/E: 61.4
ROE: 8.86%
ROCE: 12.8%
Book Value: ₹109
Dividend Yield: 0.22%
52W High / Low: ₹745/118

In Jun 2026, BLISS GVS PHARMA LTD (BLISSGVS) reported sales ₹222 Cr and net profit ₹39 Cr.

Annual TTM: sales ₹788 Cr, net profit ₹114 Cr.

Shareholding: Promoters 35.01% (Jun 2026), FIIs 8.07% (Jun 2026), DIIs 9.46% (Jun 2026), Public 47.45% (Jun 2026), No. of Shareholders 46,767% (Jun 2026).

BLISSGVS quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	183	180	156	163	190	165	212	222
Expenses	157	154	142	131	160	138	167	170
Operating Profit	25	26	14	33	30	27	44	52
OPM %	14%	14%	9%	20%	16%	16%	21%	23%
Other Income	8	12	9	11	14	8	10	9
Interest	3	1	1	5	3	1	2	0
Depreciation	6	7	7	8	8	8	8	9
Profit before tax	24	30	14	31	33	25	44	51
Tax %	29%	29%	20%	31%	26%	26%	27%	25%
Net Profit	17	21	11	21	25	19	32	39
EPS in Rs	1.62	2.00	1.09	2.00	2.35	1.76	3.06	3.64
Raw PDF	—	—	—	—	—	—	—	—

BLISSGVS profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	442	466	636	598	605	667	730	788
Expenses	342	374	527	508	498	575	596	635
Operating Profit	100	91	109	90	107	92	134	153
OPM %	23%	20%	17%	15%	18%	14%	18%	19%
Other Income	37	18	35	51	-8	36	42	40
Interest	7	4	4	10	6	7	11	6
Depreciation	9	14	14	15	24	27	31	32
Profit before tax	122	91	126	116	70	94	133	154
Tax %	24%	26%	27%	26%	28%	27%	27%	—
Net Profit	92	68	93	85	51	69	97	114
EPS in Rs	8.95	6.54	8.94	8.21	4.84	6.55	9.16	10.81
Dividend Payout %	6%	8%	6%	6%	10%	8%	11%	—

BLISSGVS balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	10	10	10	10	10	10	11	11
Reserves	593	673	745	841	927	978	1,048	1,145
Borrowings	72	93	92	90	81	78	68	13
Other Liabilities	61	79	98	139	122	84	94	176
Total Liabilities	736	855	946	1,080	1,140	1,150	1,220	1,344
Fixed Assets	79	180	175	225	326	331	369	420
CWIP	43	0	2	22	3	8	21	4
Investments	18	18	18	18	18	19	19	19
Other Assets	596	657	750	815	793	793	812	901
Total Assets	736	855	946	1,080	1,140	1,150	1,220	1,344

BLISSGVS cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	48	63	67	114	44	82	97	123
Cash from Investing Activity	-68	-60	-62	-92	-13	-66	-78	-51
Cash from Financing Activity	9	-6	-12	-13	-26	-21	-27	-75
Net Cash Flow	-11	-3	-6	9	5	-4	-7	-4
Free Cash Flow	-10	-4	59	41	-50	44	30	64
CFO/OP	102%	95%	98%	132%	90%	104%	139%	121%

BLISSGVS shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	34.82%	35.10%	35.29%	35.44%	35.39%	35.36%	35.36%	35.01%
FIIs	12.13%	13.51%	13.18%	12.65%	13.27%	14.54%	10.45%	8.07%
DIIs	6.56%	6.55%	6.55%	6.54%	5.98%	5.78%	5.04%	9.46%
Public	46.49%	44.84%	44.98%	45.37%	45.36%	44.32%	49.15%	47.45%
No. of Shareholders	52,937	49,558	49,517	46,707	44,461	43,380	44,874	46,767

BLISSGVS key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	293	334	273	234	243	241	235	229
Inventory Days	89	93	121	96	86	109	86	118
Days Payable	50	86	96	89	88	66	64	103
Cash Conversion Cycle	332	342	298	241	241	283	257	244
Working Capital Days	336	401	322	258	300	294	257	274
ROCE %	19%	18%	12%	14%	13%	11%	9%	13%

BLISSGVSUpdated 13 Oct 2026, 16:57

Bliss Gvs Pharma Ltd

BLISSGVSUpdated 13 Oct 2026, 16:57

Market Cap

₹7,124Cr.

Current Price

₹673

High / Low

₹745/118

Stock P/E

61.4

ROE8.86%

ROCE12.8%

Book Value₹109

Face Value₹1.00

Dividend Yield0.22%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	109	1	98	7	5	11	31	8	0.72
Sep 2023	171	1	129	11	6	46	26	34	3.25
Dec 2023	161	2	133	8	6	29	27	21	1.98
Mar 2024	164	2	139	-33	6	-15	-25	-11	-1.09
Jun 2024	149	1	122	7	6	26	26	19	1.85
Sep 2024	183	3	157	8	6	24	29	17	1.62
Dec 2024	180	1	154	12	7	30	29	21	2
Mar 2025	156	1	142	9	7	14	20	11	1.09
Jun 2025	163	5	131	11	8	31	31	21	2
Sep 2025	190	3	160	14	8	33	26	25	2.35
Dec 2025	165	1	138	8	8	25	26	19	1.76
Mar 2026	212	2	167	10	8	44	27	32	3.06
Jun 2026	222	0	170	9	9	51	25	39	3.64

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	313	11	227	21	5	91	34	60	5.82
Mar 2016	326	14	230	23	6	100	35	66	6.36
Mar 2017	348	9	247	9	6	95	38	59	5.73
Mar 2018	298	7	209	11	6	87	34	57	5.53
Mar 2019	427	3	331	33	6	120	38	74	7.22
Mar 2020	442	7	342	37	9	122	24	92	8.95
Mar 2021	466	4	374	18	14	91	26	68	6.54
Mar 2022	636	4	527	35	14	126	27	93	8.94
Mar 2023	598	10	508	51	15	116	26	85	8.21
Mar 2024	605	6	498	-8	24	70	28	51	4.84
Mar 2025	667	7	575	36	27	94	27	69	6.55
Mar 2026	730	11	596	42	31	133	27	97	9.16
TTM	788	6	635	40	32	154	—	114	10.81

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	35.01%
FIIs	8.07%
DIIs	9.46%
Public	47.45%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	35.06%	16.31%	6.61%	42%
Dec 2023	34.97%	15.35%	6.6%	43.08%
Mar 2024	34.97%	14.74%	6.59%	43.71%
Jun 2024	34.9%	13.24%	6.58%	45.27%
Sep 2024	34.82%	12.13%	6.56%	46.49%
Dec 2024	35.1%	13.51%	6.55%	44.84%
Mar 2025	35.29%	13.18%	6.55%	44.98%
Jun 2025	35.44%	12.65%	6.54%	45.37%
Sep 2025	35.39%	13.27%	5.98%	45.36%
Dec 2025	35.36%	14.54%	5.78%	44.32%
Mar 2026	35.36%	10.45%	5.04%	49.15%
Jun 2026	35.01%	8.07%	9.46%	47.45%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	10	358	90	97	555	82	0	19	454	555
Mar 2016	10	422	81	71	585	79	2	21	483	585
Mar 2017	10	481	75	99	666	76	2	21	567	666
Mar 2018	10	531	94	59	694	73	0	18	602	694
Mar 2019	10	593	72	61	736	79	43	18	596	736
Mar 2020	10	673	93	79	855	180	0	18	657	855
Mar 2021	10	745	92	98	946	175	2	18	750	946
Mar 2022	10	841	90	139	1080	225	22	18	815	1080
Mar 2023	10	927	81	122	1140	326	3	18	793	1140
Mar 2024	10	978	78	84	1150	331	8	19	793	1150
Mar 2025	11	1048	68	94	1220	369	21	19	812	1220
Mar 2026	11	1145	13	176	1344	420	4	19	901	1344

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	15	-19	-31	-35
Mar 2016	60	-15	-35	10
Mar 2017	38	-29	-15	-6
Mar 2018	23	16	-22	17
Mar 2019	48	-68	9	-11
Mar 2020	63	-60	-6	-3
Mar 2021	67	-62	-12	-6
Mar 2022	114	-92	-13	9
Mar 2023	44	-13	-26	5
Mar 2024	82	-66	-21	-4
Mar 2025	97	-78	-27	-7
Mar 2026	123	-51	-75	-4

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	246	280	251	346	293	334	273	234	243	241	235	229
Inventory Days	58	59	61	100	89	93	121	96	86	109	86	118
Days Payable	130	94	139	88	50	86	96	89	88	66	64	103
Cash Conversion Cycle	173	245	173	357	332	342	298	241	241	283	257	244
Working Capital Days	183	207	335	452	336	401	322	258	300	294	257	274
ROCE %	24%	23%	19%	15%	19%	18%	12%	14%	13%	11%	9%	13%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of BLISS GVS PHARMA LTD (BLISSGVS)?

The reported market capitalisation for BLISS GVS PHARMA LTD (BLISSGVS) is ₹7,124Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of BLISSGVS?

The current price shown for BLISS GVS PHARMA LTD (BLISSGVS) on Fincrux is ₹673 with a 52-week high/low of ₹745/118.

What is the P/E ratio of BLISS GVS PHARMA LTD (BLISSGVS)?

The stock P/E for BLISS GVS PHARMA LTD (BLISSGVS) is 61.4 on Fincrux, with ROE at 8.86% and ROCE at 12.8%.

What were BLISSGVS latest quarterly results?

For Jun 2026, BLISS GVS PHARMA LTD (BLISSGVS) reported sales ₹222 Cr and net profit ₹39 Cr (figures in ₹ crore unless noted).

What are BLISSGVS annual sales and net profit?

For TTM, BLISS GVS PHARMA LTD (BLISSGVS) shows sales of ₹788 Cr and net profit of ₹114 Cr on the Fincrux profit & loss statement.

Who owns BLISS GVS PHARMA LTD (BLISSGVS)?

Latest shareholding for BLISS GVS PHARMA LTD (BLISSGVS) on Fincrux: Promoters 35.01% (Jun 2026), FIIs 8.07% (Jun 2026), DIIs 9.46% (Jun 2026), Public 47.45% (Jun 2026), No. of Shareholders 46,767% (Jun 2026).

Where can I find BLISS GVS PHARMA LTD (BLISSGVS) financials?

BLISS GVS PHARMA LTD (BLISSGVS) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show BLISSGVS balance sheet and cash flow?

Yes. The BLISS GVS PHARMA LTD (BLISSGVS) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 16:57